Abstracts tagged "SLE and neuropsychiatric disorders"

Abstract Number: 1941 • 2014 ACR/ARHP Annual Meeting
Neuropsychiatric Lupus Is Substantially Unaffected By B-Cell Deficiency
Jing Wen¹, Ariel Stock², Haowei Wang³, Mark Shlomchik³, Maria Gulinello² and Chaim Putterman⁴, ¹Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric lupus (NPSLE) is one of the earliest clinical manifestations in human lupus. However, its mechanisms are not fully understood. In lupus, a compromised…
Abstract Number: 664 • 2014 ACR/ARHP Annual Meeting
The Pathogenesis of Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Brain Intrinsic Factors
Ariel Stock¹, Jing Wen², Jessica Doerner² and Chaim Putterman³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ³Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric disease is a common manifestation of systemic lupus erythematosus (SLE). Frequent presentations include depression, anxiety, memory loss and cognitive decline. The pathogenesis of…
Abstract Number: 1592 • 2013 ACR/ARHP Annual Meeting
“Lupus Headache”: Results From a Prospective, International, Inception Cohort Study
John G. Hanly¹, Murray B. Urowitz², Aidan o'Keeffe³, Caroline Gordon⁴, Sang-Cheol Bae⁵, Jorge Sanchez-Guerrero⁶, Juanita Romero-Diaz⁷, Ann E. Clarke⁸, Sasha Bernatsky⁹, Daniel J. Wallace¹⁰, E.M. Ginzler¹¹, David A. Isenberg¹², Anisur Rahman¹³, Joan T. Merrill¹⁴, Michelle A. Petri¹⁵, Paul R. Fortin¹⁶, D. D. Gladman¹⁷, Barri J. Fessler¹⁸, Graciela S. Alarcon¹⁹, Ian N. Bruce²⁰, Mary Anne Dooley²¹, Kristjan Steinsson²², Munther A. Khamashta²³, Rosalind Ramsey-Goldman²⁴, Susan Manzi²⁵, Gunnar K. Sturfelt²⁶, Ola Nived²⁷, Asad A. Zoma²⁸, R. F. van Vollenhoven²⁹, Manuel Ramos-Casals³⁰, Cynthia Aranow³¹, Meggan Mackay³², Guillermo Ruiz-Irastorza³³, Kenneth C. Kalunian³⁴, S. Sam Lim³⁵, Murat Inanc³⁶, Diane L. Kamen³⁷, Christine Peschken³⁸, Søren Jacobsen³⁹, Chris Theriault⁴⁰, Kara Thompson⁴⁰ and Vernon Farewell³, ¹Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, ⁴School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶UHN Toronto Western Hospital, Toronto, ON, Canada, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁸Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁹Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada, ¹⁰Cedars-Sinai Medical Center, Los Angeles, CA, ¹¹Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ¹²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹³Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ¹⁴Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada, ¹⁷Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁸Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁹Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²⁰Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, ²¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²²Rheumatology, Landspital Univ Hospital, Reykjavik, Iceland, ²³Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ²⁴Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁵Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ²⁶Department of Rheumatology, University Hospital Lund, Lund, Sweden, ²⁷Department of Clinical Science, Lund University, Rheumatology, Lund, Sweden, ²⁸Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ²⁹Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ³⁰Laboratorio de Enfermedades Autoinmunes Josep Font, Hospital Clínic, Barcelona, Spain, ³¹The Feinstein Institute, Manhasset, NY, ³²Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ³³Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ³⁴UCSD School of Medicine, La Jolla, CA, ³⁵Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ³⁶Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁷Department of Medicine, Medical University of South Carolina, Charleston, SC, ³⁸Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ³⁹Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴⁰Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
Background/Purpose: “Lupus headache” is controversial and is included in validated measures of global SLE disease activity. We examined the frequency and characteristics of “lupus headache”…
Abstract Number: 563 • 2013 ACR/ARHP Annual Meeting
Hold The Rituximab: Neuropsychiatric Disease In Murine Lupus Is Not B-Cell Dependent
Jing Wen¹, Ariel Stock¹, Haowei Wang², Mark Shlomchik², Maria Gulinello¹ and Chaim Putterman³, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Pittsburgh School of Medicine, Pittsburgh, PA, ³The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric disease is one of the earliest clinical manifestations in systemic lupus erythematosus (SLE). However, the mechanisms leading to neuropsychiatric SLE (NPSLE) are not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].